RxDoctor Payments Data

Szilard Voros

Cardiovascular Disease · Stony Brook, NYNPI 1831233576

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,438,380 of the $3,664,765 with a category attached, or 93.8%. Every reported general payment came from a single manufacturer, Novartis. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,664,765in general payments, 2019–2025

Across 18 payments — averaging $203,598 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3.7M
$11,248in research payments, 2019–2025

Across 4 payments — averaging $2812.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$11K

What the payments were for

  • Consulting fees$226,0636%
  • Speaking & faculty fees$3,438,38094%
  • Food & beverage$3230%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis18$3,664,765

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,664,765 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Other cardiovascular disease in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →